UBS Group
ASND icon

UBS Group’s Ascendis Pharma A/S ASND Stock Holding History

UBS Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,000
Closed -$589K – 7841
2019
Q1 		$589K Buy
+5,000
New +$438K ﹤0.01% 3957

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

UBS Group's ASND Position: Q2 2026 in Review

UBS Group increased its Ascendis Pharma A/S (ASND) stake by 94% in Q2 2026, buying an estimated $45.4M and bringing the position to 401,881 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #1071.

UBS Group first reported a position in ASND in Q1 2015 and has held it in 43 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • UBS Group held 401,881 shares of Ascendis Pharma A/S worth $107M as of Q2 2026.
  • UBS Group bought 194,542 Ascendis Pharma A/S shares in Q2 2026, an estimated $45.4M.
  • Ascendis Pharma A/S made up 0.01% of UBS Group's portfolio in Q2 2026, its #1071 holding.
  • UBS Group first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 43 quarters since.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.